Skip to NavigationSkip to content

Novartis' Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

Published on 10/10/19 at 09:41am

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs and symptoms of psoriatic arthritis in patients with and without enthesitis, a sub-group representing around 30-50% of the total incidence of the disease.

Pooled two-year data from a pair of Phase 3 studies indicated that patients taking Cosentyx achieved complete resolution of enthesitis at a faster rate than those receiving placebo, while improvement in signs and symptoms of the condition, measured on the American College of Rheumatology 50 (ACR50), and Psoriasis Area and Severity Index (PASI) scales, were sustained from the fourth month of treatment up to two years.

These results were observed in both the 300mg and 150mg formulations of the therapy.

“We are pleased that the data show rapid and sustained improvement across two years in the signs and symptoms of psoriatic arthritis with Cosentyx, regardless of whether patients have enthesitis or not,” commented Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology at Novartis. “Psoriatic arthritis is complex with multiple manifestations driving patient symptoms including enthesitis, which is often associated with more severe disease. At Novartis we are striving to reimagine care in immuno-dermatology and across all manifestations of psoriatic disease to support patients and help them achieve improved quality of life.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches